{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-036841","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2025-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.834703+00:00","generated_at":"2026-05-23T10:32:01.301696+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MindMed amends credit facility, gets $42M new term loan; total capacity up to $120M","bullets":["Restated credit facility provides up to $120M in term loans; $42M funded immediately to refinance existing debt.","Interest rate lowered to greater of 10.25% or Prime+2.75%; maturity extended to April 1, 2029.","Lenders may convert up to $7M of debt into common shares at $4.01-$9.00 per share.","Additional $28M tranche available upon clinical/regulatory milestones; $50M discretionary tranche.","Minimum liquidity covenant effective July 1, 2026 if milestones missed; waived if market cap >$500M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-036841","json":"https://secwatch.observer/filing/0001104659-25-036841.json","markdown":"https://secwatch.observer/filing/0001104659-25-036841.md","text":"https://secwatch.observer/filing/0001104659-25-036841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000110465925036841/0001104659-25-036841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000110465925036841/tm2512703d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T10:32:01.301696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e0d68d7e2a9222f78ac26cbcb61bb13e50b45b91","claim":"Definium Therapeutics, Inc. amended credit facility of up to $120.0 million with K2 HealthVentures LLC at the greater of (x) 10.25% and (y) the sum of (a) the Prime Rate as reported in T maturing April 1, 2029.","evidence_excerpt":"Agreement”). The First Amendment and the Amended Credit Agreement provide for, among other things: (i) an aggregate principal amount of term loans (the “Term Loans”) of up to $120.0 million, consisting of (A) a new Restatement First Tranche Term Loan (as defined in the Amended Credit Agreement) of $42.0 million, which was funded on the Effective Date, a portion of","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1813814/000110465925036841/0001104659-25-036841-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"up to $120.0 million"},{"label":"Counterparty","value":"K2 HealthVentures LLC"},{"label":"Rate","value":"the greater of (x) 10.25% and (y) the sum of (a) the Prime Rate as reported in T"},{"label":"Maturity","value":"April 1, 2029"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}